Sunshine Biopharma, Inc. (SBFM)
SBFM Stock Price Chart
Explore Sunshine Biopharma, Inc. interactive price chart. Choose custom timeframes to analyze SBFM price movements and trends.
SBFM Company Profile
Discover essential business fundamentals and corporate details for Sunshine Biopharma, Inc. (SBFM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
15 Feb 2022
Employees
52.00
CEO
Steve N. Slilaty
Description
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
SBFM Financial Timeline
Browse a chronological timeline of Sunshine Biopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$1.20, while revenue estimate is $8.70m.
Stock split effective on 1 Jun 2026
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2026
EPS came in at -$2.50 matching the estimated -$2.50, while revenue for the quarter reached $8.09m , meeting expectations.
Earnings released on 3 Apr 2026
EPS came in at -$3.00 falling short of the estimated -$2.70 by -11.11%, while revenue for the quarter reached $8.60m , missing expectations by -14.00%.
Earnings released on 13 Nov 2025
EPS came in at -$0.19 falling short of the estimated -$0.13 by -46.15%, while revenue for the quarter reached $9.42m , missing expectations by -15.16%.
Earnings released on 12 Aug 2025
EPS came in at -$0.39 falling short of the estimated -$0.11 by -254.55%, while revenue for the quarter reached $9.41m , missing expectations by -15.98%.
Earnings released on 15 May 2025
EPS came in at -$0.44 , while revenue for the quarter reached $8.90m .
Earnings released on 31 Mar 2025
EPS came in at -$1.01 falling short of the estimated $0.01 by -10.20k%, while revenue for the quarter reached $9.59m , missing expectations by -23.25%.
Earnings released on 5 Nov 2024
EPS came in at -$0.94 surpassing the estimated -$535.00 by +99.82%, while revenue for the quarter reached $8.44m , missing expectations by -28.52%.
Earnings released on 19 Aug 2024
EPS came in at -$9.94 falling short of the estimated -$0.60 by -1.56k%, while revenue for the quarter reached $9.30m , beating expectations by +3.37%.
Stock split effective on 8 Aug 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 20 May 2024
EPS came in at -$40.00 surpassing the estimated -$160.00 by +75.00%, while revenue for the quarter reached $7.54m , beating expectations by +7.73%.
Stock split effective on 17 Apr 2024
Shares were split 1 : 100 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 28 Mar 2024
EPS came in at -$1.00 falling short of the estimated -$0.60 by -66.67%, while revenue for the quarter reached $7.68m , beating expectations by +25.90%.
Earnings released on 13 Nov 2023
EPS came in at -$0.80 surpassing the estimated -$1.20 by +33.33%, while revenue for the quarter reached $5.96m , missing expectations by -0.71%.
Earnings released on 11 Aug 2023
EPS came in at -$40.00 surpassing the estimated -$160.00 by +75.00%, while revenue for the quarter reached $5.56m , beating expectations by +11.22%.
Earnings released on 10 May 2023
EPS came in at -$1.60 , while revenue for the quarter reached $4.89m .
Earnings released on 4 Apr 2023
EPS came in at -$30.00 , while revenue for the quarter reached $3.94m .
Earnings released on 7 Nov 2022
EPS came in at -$1.60 , while revenue for the quarter reached $132.81k .
Earnings released on 3 Aug 2022
EPS came in at -$0.60 , while revenue for the quarter reached $150.31k .
Earnings released on 6 May 2022
EPS came in at -$46.00 , while revenue for the quarter reached $122.65k .
Earnings released on 21 Mar 2022
EPS came in at $6.50 , while revenue for the quarter reached $85.12k .
Stock split effective on 9 Feb 2022
Shares were split 1 : 200 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2021
EPS came in at -$318.00 , while revenue for the quarter reached $50.38k .
Earnings released on 9 Aug 2021
EPS came in at -$242.00 , while revenue for the quarter reached $52.87k .
SBFM Stock Performance
Access detailed SBFM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
